David Dai
Stock Analyst at UBS
(2.89)
# 2,647
Out of 4,407 analysts
99
Total ratings
49.3%
Success rate
3.2%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintained: Buy | $45 | $31.27 | +43.91% | 1 | Jun 10, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $138 → $124 | $123.25 | +0.61% | 6 | Jun 10, 2026 | |
| CGEM Cullinan Therapeutics | Initiated Coverage: Buy | $24 | $13.70 | +75.18% | 7 | Jun 8, 2026 | |
| NBTX Nanobiotix | Maintained: Hold | $30 | $35.27 | -14.93% | 5 | Jun 4, 2026 | |
| KURA Kura Oncology | Maintained: Buy | $15 | $9.05 | +65.75% | 7 | Jun 3, 2026 | |
| BNTX BioNTech SE | Upgraded: Buy | $135 | $90.54 | +49.11% | 1 | May 27, 2026 | |
| ENGN enGene Therapeutics | Maintained: Hold | $9 → $2 | $1.62 | +23.46% | 4 | May 14, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $38 → $37 | $18.25 | +102.74% | 4 | May 13, 2026 | |
| CGON CG Oncology | Maintained: Buy | $90 | $59.56 | +51.11% | 4 | May 8, 2026 | |
| JANX Janux Therapeutics | Downgraded: Hold | $69 → $15 | $13.56 | +10.62% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31.00 | $13.60 | +127.94% | 13 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $0.4576 | +227.80% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $8 | $2.95 | +171.19% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $4 | $4.08 | -1.96% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $128 | $86.21 | +48.48% | 2 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $49.91 | -31.88% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $33 | $14.01 | +135.55% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $23 | $16.95 | +35.69% | 5 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $546 | $444.93 | +22.72% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $125.59 | -10.82% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $28.98 | +72.53% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ¥2,690 | $8,875.00 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | $68,000.00 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | $3,292.00 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $3.30 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $3.96 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $2.86 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $12.33 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $8.05 | n/a | 1 | Mar 30, 2022 |
Celldex Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $45
Current: $31.27
Upside: +43.91%
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $138 → $124
Current: $123.25
Upside: +0.61%
Cullinan Therapeutics
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $13.70
Upside: +75.18%
Nanobiotix
Jun 4, 2026
Maintained: Hold
Price Target: $30
Current: $35.27
Upside: -14.93%
Kura Oncology
Jun 3, 2026
Maintained: Buy
Price Target: $15
Current: $9.05
Upside: +65.75%
BioNTech SE
May 27, 2026
Upgraded: Buy
Price Target: $135
Current: $90.54
Upside: +49.11%
enGene Therapeutics
May 14, 2026
Maintained: Hold
Price Target: $9 → $2
Current: $1.62
Upside: +23.46%
Syndax Pharmaceuticals
May 13, 2026
Maintained: Buy
Price Target: $38 → $37
Current: $18.25
Upside: +102.74%
CG Oncology
May 8, 2026
Maintained: Buy
Price Target: $90
Current: $59.56
Upside: +51.11%
Janux Therapeutics
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $13.56
Upside: +10.62%
Apr 8, 2026
Maintained: Buy
Price Target: $31.00
Current: $13.60
Upside: +127.94%
Apr 2, 2026
Maintained: Hold
Price Target: $1.5
Current: $0.4576
Upside: +227.80%
Mar 18, 2026
Rated: Buy
Price Target: $7 → $8
Current: $2.95
Upside: +171.19%
Mar 5, 2026
Rated: Hold
Price Target: $2 → $4
Current: $4.08
Upside: -1.96%
Mar 3, 2026
Maintained: Buy
Price Target: $90 → $128
Current: $86.21
Upside: +48.48%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $49.91
Upside: -31.88%
Nov 10, 2025
Maintained: Buy
Price Target: $30 → $33
Current: $14.01
Upside: +135.55%
Nov 10, 2025
Maintained: Buy
Price Target: $26 → $23
Current: $16.95
Upside: +35.69%
Nov 7, 2025
Maintained: Buy
Price Target: $546
Current: $444.93
Upside: +22.72%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $125.59
Upside: -10.82%
Oct 24, 2025
Maintained: Buy
Price Target: $50
Current: $28.98
Upside: +72.53%
Apr 2, 2025
Maintained: Hold
Price Target: ¥2,690
Current: $8,875.00
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: $68,000.00
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: $3,292.00
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $3.30
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $3.96
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $40
Current: $2.86
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $54
Current: $12.33
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $8.05
Upside: n/a